• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液肿瘤伴发热性中性粒细胞减少症患者的全因死亡率及其预测因素

All-Cause Mortality and Its Predictors in Haemato-Oncology Patients with Febrile Neutropenia.

作者信息

Shmuely Haim, Monely Lea, Shvidel Lev

机构信息

Department of Internal Medicine D, Kaplan Medical Center, Rehovot 7612001, Israel.

Faculty of Medicine, Hebrew University, Jerusalem 9112001, Israel.

出版信息

J Clin Med. 2023 Aug 29;12(17):5635. doi: 10.3390/jcm12175635.

DOI:10.3390/jcm12175635
PMID:37685702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10489066/
Abstract

Febrile neutropenia (FN) is one of the most important life-threatening complications in haemato-oncology. Our objective was to report all-cause mortality rates in patients ill with a hematological malignancy (HM) hospitalized with a first FN episode and to identify predictors for mortality. We conducted a historical retrospective cohort study of consecutive patients with an HM, >18 years of age, admitted between January 2012 and August 2018 for a first episode of FN. Data on all-cause mortality 12 months after admission for FN were obtained. The Kaplan-Meier curve was used to describe mortality during the follow-up period. Univariate and multivariable analyses identified predictors for 1,3 and 12-month mortality. One hundred and fifty-eight patients (mean age 69.5, 49.4% males) were included. Overall, 54 patients died (15.8%, 25.9%, and 34.1% died after 1, 3, and 12 months, respectively). Lower serum albumin, higher serum gamma-glutamyl transferase (GGT), lower estimated glomerular filtration rate (eGFR), older age, higher temperature, and lower absolute lymphocyte count at admission were independent predictors of all-cause mortality after 12 months. Further studies are needed to confirm our results and identify therapeutic strategies to improve survival.

摘要

发热性中性粒细胞减少症(FN)是血液肿瘤学中最重要的危及生命的并发症之一。我们的目的是报告首次发生FN并因血液系统恶性肿瘤(HM)住院的患者的全因死亡率,并确定死亡率的预测因素。我们对2012年1月至2018年8月期间因首次FN发作而入院的年龄>18岁的连续HM患者进行了一项历史性回顾性队列研究。获取了FN入院后12个月的全因死亡率数据。采用Kaplan-Meier曲线描述随访期间的死亡率。单因素和多因素分析确定了1、3和12个月死亡率的预测因素。共纳入158例患者(平均年龄69.5岁,男性占49.4%)。总体而言,54例患者死亡(分别在1、3和12个月后死亡的比例为15.8%、25.9%和34.1%)。入院时血清白蛋白水平较低、血清γ-谷氨酰转移酶(GGT)较高、估计肾小球滤过率(eGFR)较低、年龄较大、体温较高以及绝对淋巴细胞计数较低是12个月后全因死亡率的独立预测因素。需要进一步研究来证实我们的结果,并确定改善生存的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6c/10489066/b39bbd17dd11/jcm-12-05635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6c/10489066/b39bbd17dd11/jcm-12-05635-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca6c/10489066/b39bbd17dd11/jcm-12-05635-g001.jpg

相似文献

1
All-Cause Mortality and Its Predictors in Haemato-Oncology Patients with Febrile Neutropenia.血液肿瘤伴发热性中性粒细胞减少症患者的全因死亡率及其预测因素
J Clin Med. 2023 Aug 29;12(17):5635. doi: 10.3390/jcm12175635.
2
Altered Pharmacokinetics Parameters of Vancomycin in Patients with Hematological Malignancy with Febrile Neutropenia, a Bayesian Software Estimation.血液系统恶性肿瘤伴发热性中性粒细胞减少症患者万古霉素药代动力学参数的改变:贝叶斯软件估计
Antibiotics (Basel). 2023 May 29;12(6):979. doi: 10.3390/antibiotics12060979.
3
Outcomes of High Risk Patients with Febrile Neutropenia at a Tertiary Care Center.三级医疗中心高危发热性中性粒细胞减少症患者的治疗结果
Asian Pac J Cancer Prev. 2017 Oct 26;18(10):2741-2745. doi: 10.22034/APJCP.2017.18.10.2741.
4
The use of serum endothelial adhesion molecules in pediatric patients with leukemia with febrile neutropenia to predict bacteremia.使用血清内皮细胞黏附分子预测伴发热性中性粒细胞减少的小儿白血病患者的菌血症。
Cytokine. 2021 Dec;148:155692. doi: 10.1016/j.cyto.2021.155692. Epub 2021 Sep 6.
5
Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.在英国一家地区癌症中心,接受常规护理的肿瘤患者中性粒细胞减少性发热的流行病学、管理和经济影响。
Ann Oncol. 2012 Jul;23(7):1889-93. doi: 10.1093/annonc/mdr520. Epub 2011 Nov 2.
6
Platelet-lymphocyte Ratio After Granulocyte Colony Stimulating Factor Administration: an Early Prognostic Marker in Septic Shock Patients With Chemotherapy-Induced Febrile Neutropenia.粒细胞集落刺激因子给药后血小板-淋巴细胞比值:化疗诱导的发热性中性粒细胞减少症败血症休克患者的早期预后标志物。
Shock. 2019 Aug;52(2):160-165. doi: 10.1097/SHK.0000000000001256.
7
FACTORS ASSOCIATED WITH TREATMENT OUTCOME OF PEDIATRIC CANCERPATIENTS ADMITTED WITH FEBRILE NEUTROPENIA IN TIKURANBESSA SPECIALIZED TEACHING HOSPITAL, ADDIS ABABA, ETHIOPIA.埃塞俄比亚亚的斯亚贝巴提库兰贝萨专科医院收治的发热性中性粒细胞减少症儿科癌症患者治疗结果的相关因素。
Ethiop Med J. 2017 Jan;55(1):43-7.
8
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.成年癌症患者发热性中性粒细胞减少症相关的死亡率、发病率和成本
Cancer. 2006 May 15;106(10):2258-66. doi: 10.1002/cncr.21847.
9
Mortality and admission to intensive care units after febrile neutropenia in patients with cancer.癌症患者发热性中性粒细胞减少症后的死亡率及入住重症监护病房情况。
Cancer Med. 2020 May;9(9):3033-3042. doi: 10.1002/cam4.2955. Epub 2020 Mar 7.
10
Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.全血细胞计数参数在预测因发热性中性粒细胞减少症而就诊于急诊科的癌症患者不良结局中的作用。
Ann Med. 2022 Dec;54(1):599-609. doi: 10.1080/07853890.2022.2031271.

引用本文的文献

1
Validation of an algorithm for identifying patients with febrile neutropenia: an epidemiological study using real-world data in Japan.一种用于识别发热性中性粒细胞减少症患者的算法的验证:一项使用日本真实世界数据的流行病学研究。
Int J Hematol. 2025 Aug 15. doi: 10.1007/s12185-025-04053-6.
2
Improving Prognostic Accuracy of MASCC Score with Lactate and CRP Measurements in Febrile Neutropenic Patients.通过测量发热性中性粒细胞减少患者的乳酸和CRP来提高MASCC评分的预后准确性
Diagnostics (Basel). 2025 Jul 31;15(15):1922. doi: 10.3390/diagnostics15151922.
3
Clinical Outcome of Febrile Neutropenia and Associated Factors Among Adult Patients with Cancer Treated at Ethiopian Oncology Centers: A Retrospective Observational Study.

本文引用的文献

1
Gamma-glutamyl transferase and risk of all-cause and disease-specific mortality: a nationwide cohort study.谷氨酰转移酶与全因和疾病特异性死亡率的关系:一项全国性队列研究。
Sci Rep. 2023 Jan 31;13(1):1751. doi: 10.1038/s41598-022-25970-0.
2
Risk factors for bloodstream infections due to extended-spectrum β-lactamase producing Enterobacteriaceae in cancer patients.癌症患者中产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的危险因素
J Infect Dev Ctries. 2018 Apr 30;12(4):265-272. doi: 10.3855/jidc.9720.
3
A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period.
埃塞俄比亚肿瘤中心接受治疗的成年癌症患者发热性中性粒细胞减少症的临床结局及相关因素:一项回顾性观察研究
Oncol Ther. 2025 Jul 16. doi: 10.1007/s40487-025-00356-0.
4
Factors Associated With Complications in Patients With Hematological Malignancies and Febrile Neutropenia: A Cohort Study.血液系统恶性肿瘤合并发热性中性粒细胞减少症患者并发症的相关因素:一项队列研究。
Cureus. 2025 Apr 5;17(4):e81750. doi: 10.7759/cureus.81750. eCollection 2025 Apr.
5
Mean Platelet Volume-to-Albumin Ratio as a Predictor of Mortality in Patients with Febrile Neutropenia: An Observational Study.平均血小板体积与白蛋白比值作为发热性中性粒细胞减少症患者死亡率的预测指标:一项观察性研究
Medicina (Kaunas). 2025 Mar 26;61(4):601. doi: 10.3390/medicina61040601.
6
Biomarkers Affecting Treatment Outcomes of Febrile Neutropenia in Hematological Patients with Lymphomas: Is Presepsin the New Promising Diagnostic and Prognostic Biomarker?影响淋巴瘤血液学患者发热性中性粒细胞减少症治疗结果的生物标志物:可溶性髓系细胞触发受体-1是新的有前景的诊断和预后生物标志物吗?
J Clin Med. 2025 Mar 25;14(7):2238. doi: 10.3390/jcm14072238.
7
Evaluation of the effects of regulatory T cells on survival outcomes in patients with acute leukemia who developed febrile neutropenia.评估调节性T细胞对发生发热性中性粒细胞减少症的急性白血病患者生存结局的影响。
J Int Med Res. 2025 Mar;53(3):3000605241276482. doi: 10.1177/03000605241276482. Epub 2025 Mar 12.
一项为期 5 年的阿根廷 515 例发热性中性粒细胞减少症的多中心前瞻性研究。
PLoS One. 2019 Oct 31;14(10):e0224299. doi: 10.1371/journal.pone.0224299. eCollection 2019.
4
Optimal Management of Neutropenic Fever in Patients With Cancer.癌症患者中性粒细胞减少性发热的最佳管理。
J Oncol Pract. 2019 Jan;15(1):19-24. doi: 10.1200/JOP.18.00269.
5
Epidemiology and source of infection in patients with febrile neutropenia: A ten-year longitudinal study.发热性中性粒细胞减少症患者的流行病学和感染源:一项十年纵向研究。
J Infect Public Health. 2019 May-Jun;12(3):364-366. doi: 10.1016/j.jiph.2018.12.006. Epub 2018 Dec 26.
6
Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases.恶性疾病化疗患者的发热性中性粒细胞减少症及长期感染风险
Open Forum Infect Dis. 2018 Oct 25;5(10):ofy255. doi: 10.1093/ofid/ofy255. eCollection 2018 Oct.
7
Factors Associated with Survival Outcomes of Febrile Neutropenia in Hematologic Malignancy Patients.血液系统恶性肿瘤患者发热性中性粒细胞减少症生存结局的相关因素
J Med Assoc Thai. 2016 Nov;99 Suppl 8:S53-S62.
8
Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.化疗引起的中性粒细胞减少症(CIN)和发热性中性粒细胞减少症(FN)对癌症治疗结果的影响:对已确立和最近出现的临床数据的概述。
Crit Rev Oncol Hematol. 2017 Dec;120:163-179. doi: 10.1016/j.critrevonc.2017.11.005. Epub 2017 Nov 11.
9
Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients.血液系统恶性肿瘤中的发热性中性粒细胞减少症:高危患者的临床和微生物学特征及结局
J Lab Physicians. 2015 Jul-Dec;7(2):116-20. doi: 10.4103/0974-2727.163126.
10
The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study.化疗剂量强度和支持性护理对早期乳腺癌患者发热性中性粒细胞减少风险的影响:一项前瞻性队列研究。
Springerplus. 2015 Aug 6;4:396. doi: 10.1186/s40064-015-1165-6. eCollection 2015.